Cover Image
市場調查報告書

全球C型肝炎市場、預測:HCV藥的銷售額及預測、臨床試驗

Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global

出版商 Renub Research 商品編碼 276657
出版日期 內容資訊 英文 87 Pages; 18 Figures; 1 Table
商品交期: 最快1-2個工作天內
價格
Back to Top
全球C型肝炎市場、預測:HCV藥的銷售額及預測、臨床試驗 Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
出版日期: 2015年08月25日 內容資訊: 英文 87 Pages; 18 Figures; 1 Table
簡介

C型肝炎市場,預計從2012年的市場規模到2018年成長3倍以上。HCV(C型肝炎病毒)感染,特徵是慢性感染疾病的高罹患率,HCV相關病患的負擔增加,低檢驗率及注射藥使用的擴大相關預計發病率增加,是複雜的公共衛生問題。HCV藥市場成長主要起因於未滿足需求高,其需求預計由強力開發平台候補藥而滿足。

本報告提供全球C型肝炎市相關的總括性調查、市場分析與預測、認證藥的銷售額與預測、各臨床實驗階段的開發平台藥物分析等等,為您概述為以下內容。

第1章 摘要整理

第2章 C型肝炎藥:市場、預測

第3章 C型肝炎:認證藥的銷售額、預測

  • Pegasys
  • Pegintron
  • Incivek
  • Victrelis

第4章 C型肝炎:契約、收購

第5章 C型肝炎:開發平台藥物臨床實驗(階段)Ⅲ

  • Simeprevir (TMC 435) (企業名: Janssen Pharmaceutical)
  • Faldaprevir (BI 201335) (企業名: Boerhinger Ingelheim)
  • Asunaprevir (BMS-650032) (企業名: Bristol-Myers Squibb)
  • Sofosbuvir (PSI-7977 or GS-7977) (企業名: Gilead Sciences)
  • Daclatasvir (BMS-790052) (企業名: Bristol-Myers Squibb)
  • BI-207127 (企業名: Boerhinger Ingelheim)
  • PEG-Interferon Lambda (企業名: Bristol-Myers Squibb)
  • ABT-450/r (Ritonavir) (企業名: Abbott Laboratories)
  • ABT-267 (企業名: Abbott Laboratories)
  • ABT-072/333 (企業名: Abbott Laboratories)
  • Alisporivir (企業名: Novartis)

第6章 C型肝炎:開發平台藥物臨床實驗(階段)Ⅱ

  • Mericitabine (RG-7128) (企業名: Roche)
  • Danoprevir/r (Ritonavir) (RG7227) (企業名: Roche)
  • GS-9256 (企業名: Gilead Sciences)
  • GS-9451 (企業名: Gilead Sciences)
  • MK-5172 (企業名: Merck)
  • Sovaprevir (ACH-1625) (企業名: Achillion)
  • IDX-320 (企業名: Idenix)
  • MK-8742 (企業名: Merck)
  • ACH-3102 (企業名: Achillion Pharmaceuticals, Inc)
  • IDX-719 (企業名: Idenix)
  • PPI-668 (企業名: Presidio Pharmaceuticals)
  • Setrobuvir (ANA-598) (企業名: Roche)
  • VX-222 (企業名: Vertex Pharmaceuticals)
  • GS-9669 (企業名: Gilead Sciences )
  • GS-9190 (Tegobuvir) (企業名: Gilead Sciences)
  • BMS-791325 (企業名: Bristol-Myers Squibb)

第7章 C型肝炎:開發平台藥物的銷售額預測

  • Simeprevir (TMC 435)
  • Faldaprevir (BI 201335) (Boerhinger Ingelheim)
  • Asunaprevir (BMS-650032)
  • Sofosbuvir (PSI-7977 or GS-7977)
  • Daclatasvir (BMS-790052)
  • ABT-450/r (Ritonavir)
  • ABT-072/333
  • Alisporivir
  • Mericitabine (RG-7128)
  • Danoprevir (RG7227)
  • GS-9256
  • Setrobuvir (ANA-598)
  • VX-222
  • GS-9190 (Tegobuvir)
  • BMS-791325

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

SUMMARY

Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.

This is 3rd edition report on Hepatitis C Drugs Industry by Renub Research. Report titled “Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.

  • 1. Hepatitis C Drugs Market & Forecast (Chapter 2)
  • 2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
  • 3. Hepatitis C - Pipeline Drugs Sales & Forecast (Chapter 4)
  • 4. Hepatitis C Deals & Acquisitions (Chapter 5)
  • 5. Hepatitis C - Company Wise Clinical Trial Analysis (Chapter 6)

Hepatitis C - Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)

  • 1. Pegasys
  • 2. Pegintron
  • 3. Incivek
  • 4. Victrelis
  • 5. Olysio
  • 6. Sovaldi/Harvoni
  • 7. HCV Franchise
  • 8. Viekira Pak

Hepatitis C - Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)

  • 1. Drug A (Merck & Co. Inc.)
  • 2. Drug B (Merck & Co. Inc.)
  • 3. Drug C (Bristol-Myers Squibb)

Hepatitis C - Company Wise Clinical Trial Analysis (Chapter No.5)

  • 1. AbbVie
  • 2. Bristol-Myers Squibb (BMS)
  • 3. Gilead Sciences
  • 4. Merck & Co. Inc.
  • 5. Tibotec/Janssen Therapeutics

DATA SOURCES

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Table of Contents

1. Executive Summary

2. Hepatitis C Drugs - Market & Forecast

3. Hepatitis C - Approved Drugs Sales & Forecast

  • 3.1. Pegasys Sales & Forecast
  • 3.2. Pegintron Sales & Forecast
  • 3.3. Incivek Sales
  • 3.4. Victrelis Sales & Forecast
  • 3.5. Olysio Sales & Forecast
  • 3.6. Sovaldi / Harvoni Sales & Forecast
  • 3.7. HCV Franchise Sales & Forecast
  • 3.8. Viekira Pak Sales & Forecast

4. Hepatitis C - Pipeline Drugs Sales Forecast

  • 4.1. Drug A of (Merck & Co. Inc.)
  • 4.2. Drug B of (Merck & Co. Inc.)
  • 4.3. Drug C of (Bristol-Myers Squibb)

5. Hepatitis C - Deals & Acquisitions

6. Hepatitis C - Company Wise Clinical Trials Analysis

  • 6.1. AbbVie - Clinical Trials
    • 6.1.1. Phase III
    • 6.1.2. Phase II
    • 6.1.3. Phase I
  • 6.2. Bristol-Myers Squibb (BMS) - Clinical Trials
    • 6.2.1. Phase III
    • 6.2.2. Phase II
  • 6.3. Gilead Sciences - Clinical Trials
    • 6.3.1. Phase II
  • 6.4. Merck & Co. Inc. - Clinical Trials
    • 6.4.1. Phase IV
    • 6.4.2. Phase III
    • 6.4.3. Phase II
    • 6.4.4. Phase I
  • 6.5. Tibotec / Janssen Therapeutics - Clinical Trials
    • 6.5.1. Phase IV
    • 6.5.2. Phase III
    • 6.5.3. Phase II
    • 6.5.4. Phase I

LIST OF FIGURES

  • Figure 2 1: Global - Hepatitis C Drug Market (Million US$), 2010 - 2014
  • Figure 2 2: Global - Forecast for Hepatitis C Drug Market (Million US$), 2015 - 2020
  • Figure 3 1: Global - Pegasys Sales (Million US$), 2005 - 2014
  • Figure 3 2: Global - Forecast for Pegasys Sales (Million US$), 2015 - 2020
  • Figure 3 3: Global - Pegintron Sales (Million US$), 2010 - 2014
  • Figure 3 4: Global - Forecast for Pegintron Sales (Million US$), 2015 - 2020
  • Figure 3 5: Global - Incivek Sales (Million US$), 2011 - 2014
  • Figure 3 6: Global - Victrelis Sales & Forecast (Million US$), 2011 - 2015
  • Figure 3 7: Global - Olysio Sales (Million US$), 2013 - 2014
  • Figure 3 8: Global - Forecast for Olysio Sales (Million US$), 2015 - 2020
  • Figure 3 9: Global - Sovaldi/Harvoni Sales (Million US$), 2013 - 2014
  • Figure 3 10: Global - Forecast for Sovaldi/Harvoni Sales (Million US$), 2015 - 2020
  • Figure 3 11: Global - HCV Franchise Sales & Forecast (Million US$), 2014 - 2020
  • Figure 3 12: Hepatitis C Drugs - Viekira Pak, Sovaldi & Harvoni Initial Prescription (Number), 2013, 2014
  • Figure 3 13: Global - Viekira Pak Sales & Forecast (Million US$), 2014 - 2020
  • Figure 4 1: Global - Forecast for Vaniprevir (MK-7009) Sales (Million US$), 2015 - 2020
  • Figure 4 2: Global - Forecast for Grazoprevir/Elbasvir (MK-5172 + MK-8742) Sales (Million US$), 2016 - 2020
  • Figure 4 3: Global - Forecast for PEG-Interferon Lambda Sales (Million US$), 2015 - 2020

LIST OF TABLES

  • Table 5 1: Hepatitis C - Deals & Acquisitions in the anti-HCV Drug Space, 2004 - 2012
Back to Top